Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887412 | 0.65 | — | — | |
| SCHEMBL7921744 | 0.62 | — | — | |
| SCHEMBL4563364 | 0.62 | — | — | |
| SCHEMBL2975537 | 0.62 | — | — | |
| SCHEMBL4022312 | 0.61 | — | — | |
| SCHEMBL9387971 | 0.60 | — | — | |
| SCHEMBL5408162 | 0.60 | — | — | |
| SCHEMBL17251674 | 0.57 | — | — | |
| SCHEMBL377551 | 0.57 | — | — | |
| SCHEMBL626926 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049530-B1 | METHOD FOR CELL-FREE PROTEIN SYNTHESIS IN THE PRESENCE OF A CASPASE INHIBITOR | FRAUNHOFER GES FORSCHUNG (DE) | 2022-06-22 | — | — | EP | disclosed |
| EP-2211865-A2 | COMBINATION COMPRISING PURINE DERIVATIVES AND OTHER COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAY DISEASES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20090238770-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| US-20090181934-A1 | Organic Compounds | NOVARTIS AG | 2009-07-16 | — | — | US | disclosed |
| WO-2009050198-A2 | COMBINATION COMPRISING PURINE DERIVATIVES AND OTHER COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| EP-1962848-A2 | COMBINATIONS OF INDACATEROL DERIVATIVES AND OTHER AGENTS FOR THE TREATMENT OF AIRWAY DISEASES | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2006128674-A2 | COMBINATIONS OF INDACATEROL DERIVATIVES AND OTHER AGENTS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| EP-1165828-A4 | 50 HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES INC (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1165828-A1 | 50 HUMAN SECRETED PROTEINS | Human Genome Sciences, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001019373-A2 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000058496-A1 | 50 HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| EP-0998300-A1 | METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-10 | — | — | EP | disclosed |
| US-5843905-A | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-01 | — | — | US | disclosed |
| US-5843905-A | Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1998041232-A2 | COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| EP-0644197-B1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | VERTEX PHARMA (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0644197-B1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | VERTEX PHARMA (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0644197-A1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0644197-A1 | Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238770-A1 | Organic compounds | LTB4R, LTB4R2, LTA4H | TDP1 3899/4885 |
| US-20090181934-A1 | Organic Compounds | LTB4R2, LTA4H, LTB4R | TDP1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.